

HOSPITAL PHYSICIAN®

PULMONARY DISEASE BOARD REVIEW MANUAL

PUBLISHING STAFF

PRESIDENT, GROUP PUBLISHER

Bruce M. White

EDITORIAL DIRECTOR

Debra Dreger

SENIOR EDITOR

Becky Krumm, ELS

ASSOCIATE EDITOR

Lamont Williams

ASSISTANT EDITOR

Jennifer M. Vander Bush

EDITORIAL ASSISTANT

Nora H. Landon

EXECUTIVE VICE PRESIDENT

Barbara T. White, MBA

EXECUTIVE DIRECTOR

OF OPERATIONS

Jean M. Gaul

PRODUCTION DIRECTOR

Suzanne S. Banish

PRODUCTION ASSOCIATES

Tish Berchtold Klus

Mary Beth Cunney

PRODUCTION ASSISTANT

Stacey Caizzo

ADVERTISING/PROJECT MANAGER

Patricia Payne Castle

MARKETING MANAGER

Deborah D. Chavis

NOTE FROM THE PUBLISHER:

This publication has been developed without involvement of or review by the American Board of Internal Medicine.



The Association for Hospital Medical Education endorses HOSPITAL PHYSICIAN for the purpose of presenting the latest developments in medical education as they affect residency programs and clinical hospital practice.

Drug-Induced Pulmonary Disease

Series Editor and Contributor:

Robert A. Balk, MD, FACP, FCCP, FCCM

Professor of Internal Medicine, Rush Medical College; Director of Pulmonary and Critical Care Medicine, Rush-Presbyterian-St. Luke's Medical Center, Chicago, IL

Contributor:

Suresh Ramasubban, MD

Fellow, Section of Pulmonary and Critical Care Medicine, Rush Medical College, and Rush-Presbyterian-St Luke's Medical Center, Chicago, IL

Table of Contents

| | |
|--|----|
| Introduction | 2 |
| Case Presentation | 2 |
| Drug-Induced Pulmonary Disease | 2 |
| Follow-up of Case Patient | 9 |
| Amiodarone-Induced Pulmonary Disease | 9 |
| Outcome of Case Patient | 10 |
| Board Review Questions | 10 |
| Answers | 11 |
| References | 11 |
| Suggested Readings | 11 |

Cover Illustration by May Cheney

Copyright 2002, Turner White Communications, Inc., 125 Strafford Avenue, Suite 220, Wayne, PA 19087-3391, www.turner-white.com. All rights reserved. No part of this publication may be reproduced, stored in a retrieval system, or transmitted in any form or by any means, mechanical, electronic, photocopying, recording, or otherwise, without the prior written permission of Turner White Communications, Inc. The editors are solely responsible for selecting content. Although the editors take great care to ensure accuracy, Turner White Communications, Inc., will not be liable for any errors of omission or inaccuracies in this publication. Opinions expressed are those of the authors and do not necessarily reflect those of Turner White Communications, Inc.

Drug-Induced Pulmonary Disease

Robert A. Balk, MD, FACP, FCCP, FCCM and Suresh Ramasubban, MD

INTRODUCTION

Drug therapy is a relatively common iatrogenic cause of pulmonary diseases, yet therapeutic-drug-induced disorders are not always suspected when a patient becomes ill. Moreover, drug toxicity is not a reportable disease; for this reason, the actual number of cases of illness due to drug therapy is unknown. It is estimated, however, that 2% to 5% of hospital admissions (involving approximately 1 million people) are related to adverse drug reactions.¹ Also, approximately 10% to 18% of hospitalized patients will experience toxic reactions to therapeutic drugs.² The overall mortality rate associated with adverse drug reactions is approximately 2% to 12%, and approximately 0.03% to 3% of all hospital deaths are related to such drug reactions.^{1,2} This manual uses a case-based discussion to review the most common medications that have caused lung injury in patients, clinical manifestations of pulmonary drug toxicity, and recommendations for treatment.

CASE PRESENTATION

INITIAL PRESENTATION AND HISTORY

A 63-year-old man presents to the office with a 4-month history of a nonproductive cough and progressively increasing dyspnea on exertion. Before this 4-month period, he could walk approximately 2 miles without dyspnea developing; however, he now experiences dyspnea after walking 1 block. He has not experienced any hemoptysis, fevers, chills, weight loss, chest pain, orthopnea, or paroxysmal nocturnal dyspnea. He is a nonsmoker and drinks alcoholic beverages on a social basis. His past medical history includes hypertension and coronary artery disease. Three years ago, he had a myocardial infarction and underwent a percutaneous coronary angioplasty procedure. Six months ago, he was found to have atrial fibrillation, which required treatment with amiodarone after attempts at chemical cardioversion with propafenone failed. He has maintained a sinus rhythm on the amiodarone treatment. His current

medications include aspirin, metoprolol, enalapril, furosemide, metolazone, and amiodarone.

PHYSICAL EXAMINATION

On physical examination, it is observed that the patient is a slender man who appears to be in no acute distress and who can sit comfortably. He is afebrile, with a regular pulse of 64 bpm, blood pressure of 146/70 mm Hg, respiratory rate of 16 breaths/min, and an oxygen saturation of 94% on room air. However, his oxygen saturation falls to 90% after walking for 5 minutes.

The patient has a regular cardiac rhythm, with a normal S₁ and S₂. No murmur or gallop is detected. There is no jugular venous distention. Inspiratory crackles over the lung bases are present on auscultation of the lungs. Results of the remainder of the physical examination are unremarkable.

- Which of the case patient's medications could be associated with his pulmonary abnormalities?

CONTINUED CLINICAL COURSE

On further review of the patient's medications, it is discovered that the dose of the amiodarone was titrated up to 800 mg/day over a period of 2 weeks. This dose was continued for an additional 2 weeks, and then the patient converted to sinus rhythm. The amiodarone dose was supposed to have been titrated down to the lowest effective maintenance dose, but the patient continued to take 800 mg/day. It is suspected that the amiodarone may be causing the patient's illness. Aspirin may also be a potential cause of pulmonary drug toxicity.

DRUG-INDUCED PULMONARY DISEASE

Since the first review of drug-induced pulmonary disease by Rosenow in 1972,² the list of medications that could potentially cause pulmonary disease has grown to include over 200 drugs. New reports continue to add medications to the list; however, it should be remembered that not all drug-induced disorders are confirmed or reported as such. Drug toxicity is not a reportable disease.